[1] |
Tsokos GC. Systemic lupus erythematosus[J]. N Engl J Med, 2011, 365: 2110-2121.
doi: 10.1056/NEJMra1100359
|
[2] |
周纬, 殷蕾, 金燕樑. 儿童系统性红斑狼疮临床特征(附47例报告)[J]. 上海医学, 2008, 31(12): 843-845.
|
[3] |
Kamphuis S, Silverman ED. Prevalence and burden of pediatric onset systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2010, 6: 538-546.
doi: 10.1038/nrrheum.2010.121
pmid: 20683438
|
[4] |
殷蕾, 周纬. 系统性红斑狼疮危象[J]. 中国小儿急救医学, 2020, 27(5): 324-329.
|
[5] |
Kazzaz NM, Coit P, Lewis EE, et al. Systemic lupus erythematosus complicated by diffuse alveolar haemorrhage: risk factors, therapy and survival[J]. Lupus Sci Med, 2015, 2(1): e000117.
|
[6] |
Ju JH, Min JK, Jung CK, et al. Lupus mesenteric vasculitis can cause acute abdominal pain in patients with SLE[J]. Nat Rev Rheumatol, 2009, 5(5): 273-281.
doi: 10.1038/nrrheum.2009.53
pmid: 19412194
|
[7] |
Alperin JM, Ortiz-Fernández L, Sawalha AH. Monogenic lupus: a developing paradigm of disease[J]. Front Immunol, 2018, 9: 2496.
doi: 10.3389/fimmu.2018.02496
pmid: 30459768
|
[8] |
Aringer M, Costenbader K, Daikh D, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78: 1151-1159.
doi: 10.1136/annrheumdis-2018-214819
pmid: 31383717
|
[9] |
Al-Mayouf SM, Akbar L, Abdwani R, et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematous in monogenic lupus[J]. Clin Rheumatol, 2022, doi: 10.1007/s10067-022-06209-9.
doi: 10.1007/s10067-022-06209-9
|
[10] |
中华医学会儿科学分会免疫学组中华儿科杂志编辑委员会. 中国儿童系统性红斑狼疮诊断与治疗指南[J]. 中华儿科杂志, 2021, 59(12) : 1009-1024.
|
[11] |
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus[J]. Arthritis Rheum, 1996, 39: 363-369.
doi: 10.1002/art.1780390303
|
[12] |
Petri M, Magder LS. Comparison of remission and lupus low disease activity state in damage prevention in a United States systemic lupus erythematosus cohort[J]. Arthritis Rheumatol, 2018, 70: 1790-1795.
doi: 10.1002/art.40571
|
[13] |
Wahadat MJ, van den Berg L, Timmermans D, et al. LLDAS is an attainable treat-to-target goal in childhood-onset SLE[J]. Lupus Sci Med, 2021, 8(1): e000571.
|
[14] |
FranklynK, LauCS, NavarraSV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS)[J]. Anna Rheuma Dis, 2015, 75 (9): 1615.
|
[15] |
van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS)[J]. Ann Rheum Dis, 2017, 76: 554-561.
doi: 10.1136/annrheumdis-2016-209519
pmid: 27884822
|
[16] |
Atar D, Birkeland KI, Uhlig T. 'Treat to target': moving targets from hypertension, hyperlipidaemia and diabetes to heumatoid arthritis[J]. Ann Rheum Dis, 2010, 69: 629-630.
doi: 10.1136/ard.2010.128462
pmid: 20237122
|
[17] |
Kumar K, Gordon C, Toescu V, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: a comparison between patients of south Asian and White British origin[J]. Rheumatology (Oxford), 2008, 47: 690-697.
doi: 10.1093/rheumatology/ken050
pmid: 18375972
|
[18] |
Mok CC, Hamijoyo L, Kasitanon N, et al. The Asia-Pacific League of Associations for Rheumatology consensus statements on the management of systemic lupus erythematosus[J]. Lancet Rheumatol, 2021, 3: e517-e531.
|
[19] |
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, et al. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review[J]. Ann Rheum Dis, 2010, 69: 20-28.
doi: 10.1136/ard.2008.101766
pmid: 19103632
|
[20] |
Mok CC, Yap DY, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia[J]. Int J Rheum Dis, 2013, 16(6): 625-636.
doi: 10.1111/1756-185X.12212
pmid: 24382275
|
[21] |
Buttgereit F, Straub RH, Wehling M, et al. Glucocorticoids in the treatment of rheumatic diseases:an update on the mechanisms of action[J]. Arthritis Rheum, 2004, 50: 3408-3417.
doi: 10.1002/art.20583
|
[22] |
Fanouriakis A, Kostopoulou M, Alunno A, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus[J]. Ann Rheum Dis, 2019, 78: 736-745.
doi: 10.1136/annrheumdis-2019-215089
pmid: 30926722
|
[23] |
KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases[J]. Kidney Int, 2021, 100(4S): S1-S276.
|
[24] |
Ginzler EM, Dooley MA, Aranow C, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis[J]. N Engl J Med, 2005, 353: 2219-2228.
doi: 10.1056/NEJMoa043731
|
[25] |
Isenberg D, Appel GB, Contreras G, et al. Influence of race/ethnicity on response to lupus nephritis treatment: the ALMS study[J]. Rheumatology (Oxford), 2010, 49: 128-140.
doi: 10.1093/rheumatology/kep346
pmid: 19933596
|
[26] |
王笑秋, 殷蕾, 茅幼英, 等. 多靶点治疗儿童狼疮肾炎的疗效观察[J]. 中华风湿病学杂志, 2014, 18(9): 47-51.
|
[27] |
Weidenbusch M, Römmele C, Schröttle A, Anders HJ. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis[J]. Nephrol Dial Transplant, 2013, 28: 106-111.
doi: 10.1093/ndt/gfs285
|
[28] |
Lorenz G, Schul L, Schraml F, et al. Adult macro-phage activation syndrome-haemophagocytic lymphohistiocytosis: ‘of plasma exchange and immunosuppressive escalation strategies’ - a single centre reflection[J]. Lupus, 2020, 29: 324-333.
doi: 10.1177/0961203320901594
pmid: 32013725
|